MeiraGTx Holdings PLC
MGTX Healthcare Biotechnology
MeiraGTx Holdings PLC’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 144.6% from fiscal 2024. In the quarter to June 2026, revenue grew 8,608.6%, EPS grew 466.7%, free cash flow grew 13.1% and total debt rose 28.6%, each against the same quarter a year earlier.
Follow MGTX
MeiraGTx Holdings PLC (MGTX) P/E ratio
As of 16 October 2026, MeiraGTx Holdings PLC (MGTX) trades at a P/E ratio of 12.2×. Over the past ten years it has ranged from 0.0× (June 2026) to 19.7× (August 2026); the current reading is higher than 96% of that period. That is above the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 17.8× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 26 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ANRO Alto Neuroscience, Inc. compare | n/m |
| MLTX MoonLake Immunotherapeutics compare | n/m |
| MNKD MannKind Corporation compare | n/m |
| SVRA Savara Inc. compare | n/m |
| AKTS Aktis Oncology, Inc. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.6× |
| MGTX MeiraGTx Holdings PLC | 12.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)